Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer
Status:
Withdrawn
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This is an open, multicenter phase II study. The purpose is to demonstrate the efficacy of
cetuximab in combination with carboplatin and vinorelbine as second line treatment in
patients with recurrent or metastatic head and neck cancer who have progressed during or
after treatment with first line cisplatinum.